SCHEMBL15056116

SCHEMBL15056116

COc1c(N)nc(-c2cc(OC)n(Cc3ccccc3F)n2)nc1-c1ccncc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GUCY1B2 O75343 4/20 0.41
▸ GUCY1A2 P33402 4/20 0.41
▸ GUCY1A1 Q02108 4/20 0.41
▸ GUCY1B1 Q02153 4/20 0.41
▸ OPRK1 P41145 1/20 0.39
▸ BUB1 O43683 9/20 0.39
▸ ADORA3 P0DMS8 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ BTK Q06187 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15056127 0.93 GUCY1B2 (0.41) GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1
SCHEMBL15055664 0.88 BUB1 (0.40) GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1
SCHEMBL15055439 0.81 BUB1 (0.42) GUCY1A1GUCY1B1BUB1ADORA3KCNH2
SCHEMBL15055827 0.78 ADORA3 (0.39) GUCY1A1GUCY1B1BUB1ADORA3KCNH2
SCHEMBL15075373 0.77 GUCY1B2 (0.53) GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1
SCHEMBL16806907 0.76 GUCY1B2 (0.64) GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1
SCHEMBL16324219 0.74 GUCY1B2 (0.45) GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1
SCHEMBL17619174 0.73 PDE5A (0.50) GUCY1A1GUCY1B1KCNH2
SCHEMBL28489041 0.72 GUCY1B2 (0.57) GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1
SCHEMBL27936415 0.71 ADORA2A (0.44) GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794596-A1 SUBSTITUTED BENZYLPYRAZOLES Bayer Intellectual Property GmbH (DE) 2014-10-29 — — EP claimed
WO-2013092512-A1 SUBSTITUTED BENZYLPYRAZOLES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-27 — — WO claimed
US-20140336176-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2014-11-13 — — US disclosed
EP-2794596-A1 SUBSTITUTED BENZYLPYRAZOLES Bayer Intellectual Property GmbH (DE) 2014-10-29 — — EP disclosed
WO-2013092512-A1 SUBSTITUTED BENZYLPYRAZOLES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336176-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD1, DRD2, DRD3 GUCY1B2 4293/4885GUCY1A2 3362/4885GUCY1A1 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback